Brought to you by 
Versicor and P&U sign potential $30mm deal
24 Mar 2000
Executive Summary
Sepracor unit Versicor and Pharmacia & Upjohn have signed a potential $30mm agreement to create oxazolidinones, a new class of antibacterials. One of P&U's most advanced oxazolidinones, Zyvox, is in Phase III trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com